TrialJAMA oncology2021

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.

Kevin Kalinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.